Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial – Intergroup Collaborative Study

[1]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[2]  P. Solal-Céligny.  3 Management of histologically indolent non-Hodgkin's lymphomas , 1996 .

[3]  A. Aisenberg,et al.  Coherent view of non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[5]  B. Coiffier,et al.  Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.

[6]  I. Bernstein,et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.

[7]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[8]  M. Kaminski,et al.  Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. , 1993, The New England journal of medicine.

[9]  M. Oken,et al.  Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[10]  I. Bernstein,et al.  Monoclonal antibody-based therapies of leukemia and lymphoma. , 1992, Blood.

[11]  M. Oken,et al.  Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Hagenbeek,et al.  Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Maloney,et al.  IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma , 1997 .

[14]  P. Solal-Céligny.  Management of histologically indolent non-Hodgkin's lymphomas. , 1996, Bailliere's clinical haematology.

[15]  T. Lister,et al.  Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.